Company profile: Generation Bio
1.1 - Company Overview
Company description
- Provider of genetic medicines including iqDNA, a DNA construct designed to carry large or multiple genes to cells, potentially treating a wide range of diseases; ctLNP, a cell-targeted lipid nanoparticle delivery system for specific tissue targeting enabling personalized, redosable treatments; and RES, a rapid enzymatic synthesis process that efficiently produces highly pure DNA constructs, aiming for global access to genetic medicines.
Products and services
- CtLNP: Cell-targeted lipid nanoparticle delivery system engineered for specific tissue targeting, enabling personalized and redosable treatments
- IqDNA: Engineered DNA construct that carries large or multiple genes to cells, potentially treating a wide range of diseases with durable expression
- RES: Rapid enzymatic synthesis manufacturing process that efficiently fabricates highly pure DNA constructs, aiming for global access to genetic medicines
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Generation Bio
American Gene Technologies
HQ: United States
Website
- Description: Provider of gene therapy solutions for infectious diseases, cancers, and inherited disorders. Offerings include AGT103-T, an autologous genetically modified cell product to repair HIV-related immune damage and enable natural control of replication; a PKU gene therapy expected to enter trials in 2025; an immuno-oncology program activating γδ T cells to destroy solid tumors; and a proprietary gene-delivery platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full American Gene Technologies company profile →
AavantiBio
HQ: United States
Website
- Description: Provider of gene transfer and gene editing therapies to treat genetic diseases; a biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AavantiBio company profile →
Beam Therapeutics
HQ: United States
Website
- Description: Provider of precision genetic medicines using base editing, including BEAM-101 for sickle cell disease; BEAM-201, an anti-CD7 CAR-T for relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma; and liver-targeting LNPs BEAM-301 and BEAM-302 to correct the R83C mutation in Glycogen Storage Disease Type 1a and the PiZ allele in severe Alpha-1 antitrypsin deficiency, plus base editing delivery technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Beam Therapeutics company profile →
Egen
HQ: United States
Website
- Description: Provider of safe, efficient delivery systems for the manufacture of nucleic acid and anti-cancer drugs and for creating products to treat human diseases, offering synthetic biocompatible delivery vehicles to deliver therapeutic genes, inhibitory RNA (siRNA & shRNA), and small molecules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Egen company profile →
DNA Therapeutics
HQ: France
Website
- Description: Provider of clinical-stage biopharmaceutical development as a privately held company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DNA Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Generation Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Generation Bio
2.2 - Growth funds investing in similar companies to Generation Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Generation Bio
4.2 - Public trading comparable groups for Generation Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →